Gemcitabine Pancreatic Cancer
Nov. 14, 2024
Hsa_circ_0074298 promotes pancreatic cancer progression and resistance to gemcitabine by sponging miR-519 to target SMOC The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer | Oncogene Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer: Molecular Therapy - Nucleic Acids Barriers and opportunities for gemcitabine in pancreatic cancer therapy | American Journal of Physiology-Cell Physiology Researchers discover new source of drug resistance in pancreatic cancer - MIT Department of Biology Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer: Molecular Therapy | Gemcitabine Pancreatic Cancer
![PDF] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with ad…](https://d3i71xaburhd42.cloudfront.net/1a6ab5ded3face432eed101b9a694517562403bb/4-Figure1-1.png){kind=link}
![GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2022/12728/1/fig-2-2x.jpg){kind=link}
![PDF] Pancreatic Cancer Chemoresistance to Gemcitabine | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e6237c2d538c2280a1a87b9df06adc1a9e204e63/12-Figure3-1.png){kind=link}
